Researchers from the University of Colorado Boulder, CU Anschutz, and Colorado State University have been working on some interesting experimental treatments aimed at helping aging and damaged joints heal, and the results have been quite promising, at least in animal studies. They’ve managed to reverse osteoarthritis signs and really improve joint health.
The new methods involve a regenerative injection meant to be delivered right into the joint, alongside a biomaterial-based repair system that encourages the body’s cells to rebuild damaged cartilage. It’s intriguing stuff.
Recently, this project gained significant support from the federal Advanced Research Projects Agency for Health (ARPA-H), which confirmed that the team will progress to the next phase of a project potentially worth up to $33.5 million. This research is part of ARPA-H’s Novel Innovations for Tissue Regeneration in Osteoarthritis (NITRO) program led by Dr. Ross Uhrich.
“In just two years, we transitioned from a bold idea to developing these therapies that demonstrate the ability to reverse osteoarthritis in animals,” said principal investigator Stephanie Bryant, who is a professor at CU Boulder. “Our aim is more than pain relief; we want to put an end to this disease.”
A New Approach to Osteoarthritis
Osteoarthritis is surprisingly common, being the third most prevalent disease in the U.S. It impacts roughly one in six people over the age of 30 globally. The condition gradually deteriorates cartilage, the padding that stops bones from grinding against each other. As it progresses, it can lead to further bone damage, alter joint structure, and, well, make daily movements pretty painful.
Unfortunately, current treatment options are rather limited. Most folks either manage their symptoms through pain relief or end up needing joint replacement surgery since there is—at least for now—no actual cure.
The Colorado researchers are tackling this issue with two distinct strategies.
One treatment seeks to repurpose an already approved drug by the Food and Drug Administration. Bryant and her team have created a special particle delivery system which allows for injections into the joint that release doses of the drug over several months.
For patients dealing with more significant damage to their cartilage or bone, the team has developed another therapy involving engineered proteins. This material is delivered via arthroscopy, hardening in place to draw the body’s own precursor cells to aid in repair.
Rapid Joint Repair in Animal Studies
When tested on animals suffering from osteoarthritis and joint injuries, the injectable treatment allowed affected joints to return to a healthy state within just four to eight weeks. That’s pretty quick.
The repair material also yielded impressive outcomes. Bryant noted that it could lead to “full regeneration and repair of the defect” when used to fill in cartilage or bone issues.
The regenerative effects were also observed in human cells taken from patients undergoing joint replacement surgeries.
NITRO, the first program rolled out by ARPA-H, aims to develop “minimally invasive therapeutics that fully regenerate damaged joints.” Two years ago, they provided the Colorado team up to $33.5 million, relying on positive outcomes, to work toward this goal.
Having wrapped up phase one successfully, the researchers are now moving on to phase two.
“It’s incredibly exciting to be part of ARPA-H’s inaugural program and to be among the first teams advancing to the second phase,” expressed Bryant.
Looking Ahead to Human Trials
Dr. Evalina Burger, a professor and chair of the Department of Orthopedics at CU Anschutz, pointed out that osteoarthritis isn’t picky; it affects people from all backgrounds. She mentioned how it impacts grandparents struggling with simple tasks due to shoulder pain, as well as athletes who might have to give up running or hockey because of knee or back issues.
“Right now, the options are often either massive, costly surgery or really nothing else. There’s not much in between,” Burger remarked, noting her keen interest in the team’s research. “This is precisely why ARPA-H is so crucial.”
Burger and Bryant foresee a future where those with early-stage osteoarthritis could receive a one-time affordable treatment that keeps their joints healthy for years. Even patients with localized cartilage or bone injuries might be able to undergo repair during a quick office visit and bounce back rapidly.
As for publishing their animal study results, the researchers plan to do so in a peer-reviewed journal later this year. Additionally, they’ve established a company called Renovare Therapeutics Inc. to facilitate the movement of this technology toward commercial availability.
If the research continues on its positive trajectory, Bryant believes they could begin clinical trials in as little as 18 months. “This could genuinely change the game for patients,” she said.
